Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review
出版年份 2023 全文链接
标题
Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review
作者
关键词
-
出版物
CANCER INVESTIGATION
Volume 41, Issue 8, Pages 739-749
出版商
Informa UK Limited
发表日期
2023-10-02
DOI
10.1080/07357907.2023.2255655
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
- (2022) Yan Meng et al. Annals of Translational Medicine
- Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report
- (2021) A. Matrone et al. ANNALS OF ONCOLOGY
- BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.
- (2021) Patrick Schoffski et al. JOURNAL OF CLINICAL ONCOLOGY
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- (2021) Justin F Gainor et al. LANCET ONCOLOGY
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
- (2021) Vivek Subbiah et al. Lancet Diabetes & Endocrinology
- RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
- (2020) Massimo Santoro et al. Genes
- Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene
- (2020) Zhixin Qiu et al. Scientific Reports
- Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
- (2020) J.J. Lin et al. ANNALS OF ONCOLOGY
- Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib
- (2020) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
- (2020) Lori J. Wirth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions
- (2020) Diana Bradford et al. CLINICAL CANCER RESEARCH
- A Phase 2 Study of Lenvatinib in Patients With RET Fusion-Positive Lung Adenocarcinoma
- (2019) Toyoaki Hida et al. LUNG CANCER
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- P2.03-44 BLU-667 Demonstrates Robust Activity in RET Fusion-Driven Intracranial Tumor Models
- (2019) E. Evans et al. Journal of Thoracic Oncology
- Selective RET kinase inhibition for patients with RET-altered cancers
- (2018) V Subbiah et al. ANNALS OF ONCOLOGY
- Management of treatment-related toxicities in advanced medullary thyroid cancer
- (2018) Marcia S. Brose et al. CANCER TREATMENT REVIEWS
- Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers
- (2018) Alexander Drilon et al. Journal of Thoracic Oncology
- A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
- (2018) Alexander Drilon et al. Cancer Discovery
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
- (2017) Alexander Drilon et al. Nature Reviews Clinical Oncology
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
- (2016) S.-H. Lee et al. ANNALS OF ONCOLOGY
- Correlative analyses ofRETand RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer
- (2016) Steven I. Sherman et al. CANCER
- Lenvatinib: Role in thyroid cancer and other solid tumors
- (2016) Maria E. Cabanillas et al. CANCER TREATMENT REVIEWS
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
- (2014) K Tsuta et al. BRITISH JOURNAL OF CANCER
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer
- (2011) Anderson Ryan INTERNATIONAL JOURNAL OF ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started